We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is HealthEquity (HQY) Down 0.7% Since Last Earnings Report?
Read MoreHide Full Article
A month has gone by since the last earnings report for HealthEquity (HQY - Free Report) . Shares have lost about 0.7% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is HealthEquity due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
HealthEquity Q1 Earnings Beat Estimates, FY22 View Up
HealthEquity reported adjusted earnings per share of 38 cents for first-quarter fiscal 2022, which beat the Zacks Consensus Estimate by 22.6%. However, the bottom line fell 11.6% on a year-over-year basis.
GAAP loss per share in the fiscal first quarter was 3 cents against the year-ago period’s earnings per share of 3 cents.
Revenues in Detail
For the fiscal first quarter, the company generated revenues of $184.2 million, outpacing the Zacks Consensus Estimate by 0.6%. However, the top line dipped 3.1% from the prior-year quarter.
HSA Details
As of Apr 30, 2021, the total number of HSA for which HealthEquity served as a non-bank custodian (HSA members) came in at 5.8 million, up 8.7% year over year.
Additionally, total Active HSA assets were $15 billion at the end of the reported quarter, up 30.5% year over year. Total Accounts as of Apr 30, 2021 were 12.8 million, up 0.9% year over year. This uptick included total HSAs as well as 6.9 million CDB.
Revenue Sources
HealthEquity derives revenues from three sources, namely Service revenues, Custodial revenues and Interchange revenues.
Service revenues totaled $102.5 million, down 7.9% year over year, primarily due to a significant (more than 60%) decrease in active commuter accounts. However, the segment was benefited by growth in HSAs and other CDBs.
Custodial revenues totaled $46.9 million, up by 0.2% from the year-ago period. Per management, growth in average HSA cash with yield and a significant uptick in average HSA investments with yield more than offset a 33-basis point (bps) fall in the annualized yield on HSA cash.
Interchange revenues totaled $34.7 million, up 8.9% year over year. The revenue outperformance was primarily led by a rebound in spend across HealthEquity’s platforms in the reported quarter and growth in average total accounts.
Margin Details
In the quarter under review, HealthEquity’s gross profit fell 4.6% to $103.1 million. Gross margin contracted 90 bps to 55.9%.
Meanwhile, sales and marketing expenses rose 22.9% to $14.1 million year over year. Technology and development expenses climbed 14.1% year over year to $35.5 million whereas general and administrative expenses grew 8.9% year over year to $20.7 million. Adjusted operating expenses of $70.2 million increased 14.2% year over year.
Adjusted operating profit totaled $32.9 million, declining 29.4% from the prior-year quarter. Further, adjusted operating margin in the quarter contracted a huge 665 bps to 17.8%.
Financial Position
The company exited first-quarter fiscal 2022 with cash and cash equivalents of $736.8 million compared with $328.8 million at the end of fiscal 2021. Total debt in the fiscal first quarter (net of issuance costs) is $972.3 million compared with $986.7 million at the end of fiscal 2021.
Net cash flow from operating activities in the quarter totaled $30.9 million, up from $15 million in the year-ago period.
FY22 Guidance
HealthEquity, on the basis of its fiscal first quarter performance, raised its earlier provided financial outlook for full fiscal.
For fiscal 2022, revenues are now projected in the range of $755 million-$765 million (up from the earlier projection in the band of $750 million-$760 million). The Zacks Consensus Estimate for the same is currently pegged at $756.2 million.
Adjusted earnings per share is expected within $1.45-$1.50, up from the previous estimate of $1.37-$1.42. The Zacks Consensus Estimate for the same currently stands at $1.40.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in fresh estimates. The consensus estimate has shifted 11.87% due to these changes.
VGM Scores
At this time, HealthEquity has a subpar Growth Score of D, however its Momentum Score is doing a lot better with a B. However, the stock was allocated a grade of F on the value side, putting it in the fifth quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions looks promising. Notably, HealthEquity has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Is HealthEquity (HQY) Down 0.7% Since Last Earnings Report?
A month has gone by since the last earnings report for HealthEquity (HQY - Free Report) . Shares have lost about 0.7% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is HealthEquity due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
HealthEquity Q1 Earnings Beat Estimates, FY22 View Up
HealthEquity reported adjusted earnings per share of 38 cents for first-quarter fiscal 2022, which beat the Zacks Consensus Estimate by 22.6%. However, the bottom line fell 11.6% on a year-over-year basis.
GAAP loss per share in the fiscal first quarter was 3 cents against the year-ago period’s earnings per share of 3 cents.
Revenues in Detail
For the fiscal first quarter, the company generated revenues of $184.2 million, outpacing the Zacks Consensus Estimate by 0.6%. However, the top line dipped 3.1% from the prior-year quarter.
HSA Details
As of Apr 30, 2021, the total number of HSA for which HealthEquity served as a non-bank custodian (HSA members) came in at 5.8 million, up 8.7% year over year.
Additionally, total Active HSA assets were $15 billion at the end of the reported quarter, up 30.5% year over year. Total Accounts as of Apr 30, 2021 were 12.8 million, up 0.9% year over year. This uptick included total HSAs as well as 6.9 million CDB.
Revenue Sources
HealthEquity derives revenues from three sources, namely Service revenues, Custodial revenues and Interchange revenues.
Service revenues totaled $102.5 million, down 7.9% year over year, primarily due to a significant (more than 60%) decrease in active commuter accounts. However, the segment was benefited by growth in HSAs and other CDBs.
Custodial revenues totaled $46.9 million, up by 0.2% from the year-ago period. Per management, growth in average HSA cash with yield and a significant uptick in average HSA investments with yield more than offset a 33-basis point (bps) fall in the annualized yield on HSA cash.
Interchange revenues totaled $34.7 million, up 8.9% year over year. The revenue outperformance was primarily led by a rebound in spend across HealthEquity’s platforms in the reported quarter and growth in average total accounts.
Margin Details
In the quarter under review, HealthEquity’s gross profit fell 4.6% to $103.1 million. Gross margin contracted 90 bps to 55.9%.
Meanwhile, sales and marketing expenses rose 22.9% to $14.1 million year over year. Technology and development expenses climbed 14.1% year over year to $35.5 million whereas general and administrative expenses grew 8.9% year over year to $20.7 million. Adjusted operating expenses of $70.2 million increased 14.2% year over year.
Adjusted operating profit totaled $32.9 million, declining 29.4% from the prior-year quarter. Further, adjusted operating margin in the quarter contracted a huge 665 bps to 17.8%.
Financial Position
The company exited first-quarter fiscal 2022 with cash and cash equivalents of $736.8 million compared with $328.8 million at the end of fiscal 2021. Total debt in the fiscal first quarter (net of issuance costs) is $972.3 million compared with $986.7 million at the end of fiscal 2021.
Net cash flow from operating activities in the quarter totaled $30.9 million, up from $15 million in the year-ago period.
FY22 Guidance
HealthEquity, on the basis of its fiscal first quarter performance, raised its earlier provided financial outlook for full fiscal.
For fiscal 2022, revenues are now projected in the range of $755 million-$765 million (up from the earlier projection in the band of $750 million-$760 million). The Zacks Consensus Estimate for the same is currently pegged at $756.2 million.
Adjusted earnings per share is expected within $1.45-$1.50, up from the previous estimate of $1.37-$1.42. The Zacks Consensus Estimate for the same currently stands at $1.40.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in fresh estimates. The consensus estimate has shifted 11.87% due to these changes.
VGM Scores
At this time, HealthEquity has a subpar Growth Score of D, however its Momentum Score is doing a lot better with a B. However, the stock was allocated a grade of F on the value side, putting it in the fifth quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions looks promising. Notably, HealthEquity has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.